CD274 and non-small cell lung carcinoma: In addition, there was no difference in OS in SMARCA4-mutated NSCLC patients (N = 39) vs. SMARCA4 WT (N = 491) whether the patients were PDL-1 high or negative when treated with atezolizumab (HR = 1.185, p = 0.513) [27].